Spots Global Cancer Trial Database for Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
Official Title: Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
Study ID: NCT00148993
Conditions
Interventions
Study Description
Brief Summary: The goal of this study is to apply allogeneic tumor cell vaccination for immunotherapy in patients with micro-metastatic disease and/or in patients at high risk disease progression. The present study will use allogeneic tumor cell lines for tumor cell vaccines that share MHC determinants with the patient aiming to overcome possible restriction of antigen presentation.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI), Tel Aviv, , Israel
Contact Details
Name: shimon slavin, MD
Affiliation: The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
